Background: The efficacy of fluconazole (FLU), amphotericin B (AMB) and caspofungin (CAS) was tested against three Candida orthopsilosis, three C. metapsilosis and two C. parapsilosis sensu stricto isolates in neutropenic mice. Methods: Mice were immunosuppressed by 200 mg/kg cyclophosphamide. Five-day intraperitoneal treatment was started 24 h after infection. Kidney burden was analyzed using the Kruskal-Wallis test. Results: FLU 10 and 20 mg/kg as well as AMB 1 mg/kg significantly decreased the fungal burden (p < 0.05) for all eight isolates of the three species. CAS 2 and 5 mg/kg were efficacious against all C. orthopsilosis and C. metapsilosis isolates (p < 0.05), but only 5 mg/kg CAS was effective against C. parapsilosis isolates (p < 0.05). Conclusions: The efficacy of FLU and AMB against the three species was comparable. Though the activity of CAS was higher against C. orthopsilosis and C. metapsilosis, the current treatment guidelines for C. parapsilosis sensu stricto seem to be applicable to other ‘psilosis’ species.

1.
Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC: Candida orthopsilosis and Candida metapsilosis spp. nov., to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005;43:284–292.
2.
Lockhart SR, Messer SA, Pfaller MA, Diekema DJ: Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis, in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008;46:2659–2664.
3.
Gácser A, Schäfer W, Nosanchuk JS, Salomon S, Nosanchuk JD: Virulence of Candida parapsilosis,Candida orthopsilosis, and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol 2007;44:1336–1341.
4.
Orsi CF, Colombari B, Blasi E: Candida metapsilosis as the least virulent member of the ‘C. parapsilosis’ complex. Med Mycol 2010;48:1024–1033.
5.
van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens DA: Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008;62:106–109.
6.
Gómez-López A, Alastruey-Izquierdo A, Rodríguez D, Almirante B, Pahissa A, Rodríguez- Tudela JL, Cuenca-Estrella M, the Barcelona Candidemia Project Study Group: Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008;52:1506–1509.
7.
Varga I, Sóczó G, Kardos G, Borbély A, Szabó Z, Kemény-Beke A, Majoros L: Comparison of killing activity of caspofungin against Candida parapsilosis, C. orthopsilosis and C. metapsilosis. J Antimicrob Chemother 2008;62:1466–1468.
8.
Szabó Z, Szilágyi J, Tavanti A, Kardos G, Rozgonyi F, Bayegan S, Majoros L: In vitro efficacy of 5 antifungal agents against Candida parapsilosis,Candida orthopsilosis, and Candida metapsilosis as determined by time-kill methodology. Diagn Microbiol Infect Dis 2009;64:283–288.
9.
Cantón E, Espinel-Ingroff A, Pemán J, del Castillo L: In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 2010;54:2194–2197.
10.
Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS: A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008;52:2305–2312.
11.
Carrillo-Muñoz AJ, Quindós G, del Valle O, Santos P, Giusiano G, Ezkurra PA, Estivill MD, Casals JB: Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets. Chemotherapy 2008;54:38–42.
12.
Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, Brobeil A, Mieth M, Hofer S, Sonntag HG, Hoppe-Tichy T, Weigand MA: Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy 2009;55:418–424.
13.
Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, ed 3. CLSI document M27-A3. Wayne, Clinical and Laboratory Standards Institute, 2008.
14.
Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing: Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010;13:180–195.
15.
Kunz AN, Brook I: Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy 2010;56:492–500.
16.
Mohammadtaheri Z, Pourpaki M, Mohammadi F, Namdar R: Surveillance of antimicrobial susceptibility among bacterial isolates from intensive care unit patients of a tertiary-care university hospital in Iran: 2006–2009. Chemotherapy 2010;56:478–484.
17.
Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, the CLSI Subcommittee for Antifungal Testing: Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011;14:164–176.
18.
Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America: Clinical Practice Guidelines for the management of candidiasis: update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503–535.
19.
Hope WW, Drusano GL: Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect 2009;15:602–612.
20.
Louie A, Banerjee P, Drusano GL, Shayegani M, Miller MH: Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother 1999;43:2841–2847.
21.
Flattery AM, Hickey E, Gill CJ, Powles MA, Misura AS, Galgoci AM, Ellis JD, Zhang R, Sandhu P, Ronan J, Abruzzo GK: Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrob Agents Chemother 2011;55:3491–3497.
22.
Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002;46:739–745.
23.
Migoya EM, Mistry GC, Stone JA, Comisar W, Sun P, Norcross A, Bi S, Winchell GA, Ghosh K, Uemera N, Deutsch PJ, Wagner JA: Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol 2011;51:202–211.
24.
Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, Scalise G: Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006;50:2719–2727.
25.
Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA, Caspofungin High-Dose Study Group: A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009;48:1676–1684.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.